Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Half In Rare Diseases
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
